ADCs, GLP-1s, and Beyond: How China is Impacting the 2026 BD Landscape
June 22, 2026
32AB
Type: Breakout Session
Focus Area:
Business Development and Investment
Since 2023, the China biotech industry has made great advancements in therapeutic innovation. Initially, innovation was predominantly in oncology; however, since 2025 we have seen more and more projects in the therapeutic areas of immunology, neurology, ophthalmology and obesity. China is one of the frontrunners incorporating Artificial Intelligence (AI) into drug discovery, which strengthens and elevates their potential to drive even more biopharmaceutical innovation. This panel will address the current speed of innovation and provide predictions on how the future will unfold. Venture capital investors, CEOs and strategy experts will elaborate on their latest thinking and how to act on it.
Moderator
Speakers
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}